XML 40 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue:        
Total revenue $ 44,032 $ 33,174 $ 111,320 $ 248,603
Operating costs and expenses:        
Cost of goods sold $ 2,207 $ 242 $ 6,253 $ 242
Cost, Product and Service [Extensible List] us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember
Research and development $ 58,476 $ 49,963 $ 174,792 $ 152,467
Selling, general and administrative (48,981) 35,823 64,157 84,772
Total operating costs and expenses 11,702 86,028 245,202 237,481
Income (loss) from operations 32,330 (52,854) (133,882) 11,122
Interest and other, net        
Interest expense (580) (702) (1,864) (2,209)
Interest income and other, net (includes $(13), $0, $(13) and $0 from a related party) 1,469 4,193 5,279 12,496
Total interest and other, net 889 3,491 3,415 10,287
Income (loss) before income taxes 33,219 (49,363) (130,467) 21,409
Provision for income taxes 215 76 190 256
Net income (loss) $ 33,004 $ (49,439) $ (130,657) $ 21,153
Net income (loss) per share:        
Basic $ 0.36 $ (0.57) $ (1.46) $ 0.24
Diluted $ 0.35 $ (0.57) $ (1.46) $ 0.23
Weighted average number of common shares used to calculate net income (loss) per share:        
Basic 90,558 87,007 89,414 86,390
Diluted 93,678 87,007 89,414 91,995
License Revenue [Member]        
Revenue:        
Total revenue $ 0 $ 11,935 $ 0 $ 162,517
Development and Other Revenue [Member]        
Revenue:        
Total revenue 20,663 20,660 59,065 85,507
Product Revenue, Net [Member]        
Revenue:        
Total revenue 22,683 579 43,331 579
Drug Product Revenue [Member]        
Revenue:        
Total revenue $ 686 $ 0 $ 8,924 $ 0